CARLSBAD, Calif., Feb. 4, 2016 /PRNewswire/ -- ALASTIN™ Skincare, Inc. (www.alastin.com) —a specialty skincare company dedicated to developing and marketing innovative, clinically-tested skin care products that enhance, protect, and maintain healthy skin for a lifetime—has announced the appointment of Lynn Salo to the company's board of directors effective January 1, 2016.
Ms. Salo has 27 years of experience with Allergan in the U.S., Canada, and Europe, including her role as Vice President, Sales and Marketing for the Facial Aesthetics Division, which generated $1billion in revenue in 2015. During her tenure at Allergan, she also managed five different business units including ophthalmology, neurosciences, urology, plastic surgery, and facial aesthetics. Her experience includes launching multiple key Allergan products such as BOTOX®, VOLUMA®, LUMIGAN® and others. She holds a Bachelor of Science in microbiology from the University of Toronto, and an MBA from the University of Southern California.
Diane S. Goostree, President and CEO of ALASTIN™ Skincare, shared her enthusiasm for the addition of Ms. Salo. "Lynn's appointment furthers our commitment to scientific innovation, business integrity and our customer-centric model. She is an accomplished executive who was instrumental in the growth and continued success of Allergan's aesthetic business. Her reputation and relationships in this field are unsurpassed and we are thrilled to have her join our board."
About ALASTIN™ Skincare, Inc.:
ALASTIN™ Skincare is dedicated to developing innovative, clinically-tested skin care products that correct, protect and maintain healthy skin for a lifetime. Our unparalleled procedure enhancement products are formulated with a combination of proprietary peptides using the latest technology and are clinically tested to ensure both safety and effectiveness to reawaken the skin's youthful processes.
BOTOX®, VOLUMA® and LUMIGAN® are registered trademarks of Allergan, Inc.
SOURCE ALASTIN Skincare, Inc.